Background Thrombotic complications are considered among the main extrapulmonary
manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of …

Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We
hypothesized that therapeutic anticoagulation would improve outcomes in critically ill …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Simple Summary The aims of this study are:(1) to analyze the risk of vein thrombosis and
pulmonary embolism in patients affected by pneumonia due to Covid-19;(2) to evaluate …